XML 70 R37.htm IDEA: XBRL DOCUMENT v3.23.3
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Biogen MA, Inc. (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 15, 2023
USD ($)
Mar. 31, 2023
USD ($)
May 31, 2020
USD ($)
Apr. 30, 2020
USD ($)
product_target
$ / shares
shares
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2020
USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Number of additional neurological disease gene targets (in product targets) | product_target       7            
Accounts receivable         $ 1,148,000   $ 1,148,000   $ 3,678,000  
General and administrative expense         13,918,000 $ 16,238,000 48,068,000 $ 46,239,000    
Biogen MA, Inc.                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Change in estimate of transaction price, increase in revenue $ 127,100,000                  
Biogen MA, Inc. | License and Service                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Fixed consideration       $ 204,600,000            
Remaining performance obligation amount         0   0   151,300,000  
Cumulative catch-up to expense   $ 2,500,000                
General and administrative expense         0 $ 100,000 2,600,000 $ 400,000    
Biogen MA, Inc. | Stock Purchase Agreement                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Sale of stock, number of shares issued in transaction (in shares) | shares       24,420,157            
Sale of stock, price per share (in dollars per share) | $ / shares       $ 9.2137            
Consideration received on transaction       $ 225,000,000            
Sale of stock, excess consideration received on transaction       79,600,000            
Collaboration agreement, equity issued       145,400,000            
Accounts receivable         0   0   500,000  
Deferred revenue         0   0   $ 132,200,000  
Biogen MA, Inc. | Collaboration And License Agreement                    
Research and Development Arrangement, Contract to Perform for Others [Line Items]                    
Proceeds from collaborators     $ 125,000,000 $ 125,000,000            
Number of neurological disease gene targets selected by counterparty (in product targets) | product_target       4            
Financial advisory fees                   $ 7,000,000
Percent of initial recognition       2.00%            
Contract with customer, asset, after allowance for credit Loss         $ 4,100,000   $ 4,100,000